Stereotactic Body Radiation Therapy for Oligometastasis: GUst Do It?

Rachel M Glicksman¹, David A Palma², Matthew P Deek³, C Jillian Tsai⁴, Steve Chmura⁵, Shankar Siva⁶, Piet Ost⁷, Phuoc T Tran⁸, Alejandro Berlin⁹

Affiliations

¹ Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network; Department of Radiation Oncology, University of Toronto, Canada. Electronic address: rachelmglicksman@gmail.com.
² Department of Radiation Oncology, London Health Sciences Centre, Canada.
³ Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Jersey.
⁴ Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York.
⁵ University of Chicago Comprehensive Cancer Center, Chicago, Illinois.
⁶ Department of Radiation Oncology, Peter MacCallum Cancer Centre; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Australia.
⁷ Department of Radiation Oncology, Iridium Network, Wilrijk, Belgium.
⁸ Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland.
⁹ Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; Techna Institute, University Health Network; Department of Radiation Oncology, University of Toronto, Canada.

PMID: 36244387
DOI: 10.1016/j.ijrobp.2022.07.026

Editorial

Stereotactic Body Radiation Therapy for Oligometastasis: GUst Do It?

Rachel M Glicksman et al. Int J Radiat Oncol Biol Phys. 2022.

. 2022 Nov 15;114(4):561-570.

doi: 10.1016/j.ijrobp.2022.07.026. Epub 2022 Oct 13.

Authors

Rachel M Glicksman¹, David A Palma², Matthew P Deek³, C Jillian Tsai⁴, Steve Chmura⁵, Shankar Siva⁶, Piet Ost⁷, Phuoc T Tran⁸, Alejandro Berlin⁹

Affiliations

¹ Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network; Department of Radiation Oncology, University of Toronto, Canada. Electronic address: rachelmglicksman@gmail.com.
² Department of Radiation Oncology, London Health Sciences Centre, Canada.
³ Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Jersey.
⁴ Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York.
⁵ University of Chicago Comprehensive Cancer Center, Chicago, Illinois.
⁶ Department of Radiation Oncology, Peter MacCallum Cancer Centre; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Australia.
⁷ Department of Radiation Oncology, Iridium Network, Wilrijk, Belgium.
⁸ Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland.
⁹ Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; Techna Institute, University Health Network; Department of Radiation Oncology, University of Toronto, Canada.

PMID: 36244387
DOI: 10.1016/j.ijrobp.2022.07.026

No abstract available

PubMed Disclaimer

Comment on

Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.
Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, Lambert B, Delrue L, Bultijnck R, Claeys T, Goetghebeur E, Villeirs G, De Man K, Ameye F, Billiet I, Joniau S, Vanhaverbeke F, De Meerleer G. Ost P, et al. J Clin Oncol. 2018 Feb 10;36(5):446-453. doi: 10.1200/JCO.2017.75.4853. Epub 2017 Dec 14. J Clin Oncol. 2018. PMID: 29240541 Clinical Trial.
Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial.
Siva S, Bressel M, Murphy DG, Shaw M, Chander S, Violet J, Tai KH, Udovicich C, Lim A, Selbie L, Hofman MS, Kron T, Moon D, Goad J, Lawrentschuk N, Foroudi F. Siva S, et al. Eur Urol. 2018 Oct;74(4):455-462. doi: 10.1016/j.eururo.2018.06.004. Epub 2018 Jun 29. Eur Urol. 2018. PMID: 30227924 Clinical Trial.
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.
Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, Rowe SP, Ross AE, Gorin MA, Deville C, Greco SC, Wang H, Denmeade SR, Paller CJ, Dipasquale S, DeWeese TL, Song DY, Wang H, Carducci MA, Pienta KJ, Pomper MG, Dicker AP, Eisenberger MA, Alizadeh AA, Diehn M, Tran PT. Phillips R, et al. JAMA Oncol. 2020 May 1;6(5):650-659. doi: 10.1001/jamaoncol.2020.0147. JAMA Oncol. 2020. PMID: 32215577 Free PMC article. Clinical Trial.
Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma.
McBride S, Sherman E, Tsai CJ, Baxi S, Aghalar J, Eng J, Zhi WI, McFarland D, Michel LS, Young R, Lefkowitz R, Spielsinger D, Zhang Z, Flynn J, Dunn L, Ho A, Riaz N, Pfister D, Lee N. McBride S, et al. J Clin Oncol. 2021 Jan 1;39(1):30-37. doi: 10.1200/JCO.20.00290. Epub 2020 Aug 21. J Clin Oncol. 2021. PMID: 32822275 Free PMC article. Clinical Trial.
Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study.
Chalkidou A, Macmillan T, Grzeda MT, Peacock J, Summers J, Eddy S, Coker B, Patrick H, Powell H, Berry L, Webster G, Ostler P, Dickinson PD, Hatton MQ, Henry A, Keevil S, Hawkins MA, Slevin N, van As N. Chalkidou A, et al. Lancet Oncol. 2021 Jan;22(1):98-106. doi: 10.1016/S1470-2045(20)30537-4. Lancet Oncol. 2021. PMID: 33387498
Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis.
Glicksman RM, Metser U, Vines D, Valliant J, Liu Z, Chung PW, Bristow RG, Finelli A, Hamilton R, Fleshner NE, Perlis N, Zlotta AR, Green D, Bayley A, Helou J, Raman S, Kulkarni G, Catton C, Lam T, Chan R, Warde P, Gospodarowicz M, Jaffray DA, Berlin A. Glicksman RM, et al. Eur Urol. 2021 Sep;80(3):374-382. doi: 10.1016/j.eururo.2021.02.031. Epub 2021 Mar 6. Eur Urol. 2021. PMID: 33685838 Clinical Trial.
Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET): Extended Long-Term Outcomes.
Harrow S, Palma DA, Olson R, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, Schellenberg D, Ahmad B, Senthi S, Swaminath A, Kopek N, Liu M, Schlijper R, Bauman GS, Laba J, Qu XM, Warner A, Senan S. Harrow S, et al. Int J Radiat Oncol Biol Phys. 2022 Nov 15;114(4):611-616. doi: 10.1016/j.ijrobp.2022.05.004. Epub 2022 May 26. Int J Radiat Oncol Biol Phys. 2022. PMID: 35643253 Clinical Trial.
Extended Results and Independent Validation of a Phase 2 Trial of Metastasis-Directed Therapy for Molecularly Defined Oligometastatic Prostate Cancer.
Glicksman RM, Ramotar M, Metser U, Chung PW, Liu Z, Vines D, Finelli A, Hamilton R, Fleshner NE, Perlis N, Zlotta AR, Bayley A, Helou J, Raman S, Kulkarni G, Catton C, Lam T, Chan R, Warde P, Gospodarowicz M, Jaffray DA, Berlin A. Glicksman RM, et al. Int J Radiat Oncol Biol Phys. 2022 Nov 15;114(4):693-704. doi: 10.1016/j.ijrobp.2022.06.080. Epub 2022 Aug 27. Int J Radiat Oncol Biol Phys. 2022. PMID: 36031465 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Stereotactic Body Radiation Therapy for Oligometastasis: GUst Do It?

Affiliations

Stereotactic Body Radiation Therapy for Oligometastasis: GUst Do It?

Authors

Affiliations

Comment on

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources